NCT03888092已完成1 期
A Phase Ib, Multi-center, Open-label Study of Z650 in Advanced Esophageal Squamous Cell Carcinoma (ECSS) With Epidermal Growth Factor Receptor (EGFR) Over Expression or Gene Amplification
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 81
- 试验地点
- 1
- 主要终点
- Number of patients with adverse events (AEs) as a measure of safety and tolerability
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of Z650 in Advanced Esophageal Squamous Cell Carcinoma patients With EGFR Over expression or Gene Amplification.
详细描述
It is a multi-center , open-label, singer arm study to explore the safety and efficacy of Z650 in advanced ESCC patients who had experienced systematic chemotherapy. Approximately 45 subjects will be enrolled, each subjects will receive oral Z650, at dose of 350 mg/d, repeatedly until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed Stage IIIB or IV ESCC
- •At least experienced one regimens of chemotherapy prior to study
- •Histological or cytological evidence of EGFR overexpression or gene copy number increased
- •Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
- •Toxicity recovered to NCI CTCAE v.4.03 Grade ≤1 from previous treatments (except alopecia)
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- •Life expectancy of ≥ 12 weeks
- •Adequate organ function
- •Subject Consent
- •Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to performing this study.
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
排除标准
- •Prior treatments
- •EGFR targeted therapy, or major surgery within 4 weeks prior to study treatment
- •Nitrosourea and mitomycin chemotherapy within 6 weeks prior to study treatment
- •Had received any investigational agent from other clinical study within 4 weeks prior to study treatment or are currently participating in other clinical trials
- •Gastrointestinal diseases that could affect the absorption of Z650, (e.g., serious swallowing obstruction, chronic diarrhea, bowel obstruction);
- •Symptomatic, untreated or unstable central nervous system metastases (patient are only permitted if treated, asymptomatic and stable for at least 4 weeks prior to start of study treatment)
- •History of interstitial lung disease
- •Uncontrolled hypertension that require more than two anti-hypertensive agents to control, or systolic blood pressure (BP) >140mmHg or diastolic BP >90 mmHg before the first administration
- •Doppler ultrasound evaluation of Left ventricular ejection fraction < 50%
- •Male with QTc interval > 450 ms or female with QTc interval > 470 ms
- •History of immunodeficiency, or other acquired or congenital immunodeficiency, or history of organ transplantation
- •Any disease of the following bellowed within 6 months prior to administration:
- •Myocardial infarction, or unstable angina, coronary or peripheral artery bypass graft, congestive heart failure, or cerebrovascular events (including transient ischemic attack)
- •Active infection of hepatitis B virus (HBV)/hepatitis C virus (HCV), or infection of Human immunodeficiency virus (HIV)
- •Other malignancies within 5 years prior to enrollment, with the exception of carcinoma in situ of the cervix, basal or squamous cell skin cancer
- •History of serious allergic reactions attributed to excipients of Z650, including mannitol, sodium carboxymethyl starch, aerosol, magnesium stearate and silicified microcrystalline cellulose
- •Pregnant women, or patients not agree to use of effective contraceptions during the study or within 6 month after the study
- •Any other reason the investigator considers the patient is not suitable to participate in the study
研究组 & 干预措施
Z650 , Single-arm
Experimental
Z650 will be administered daily, at dose of 350 mg orally
干预措施: Z650 (Drug)
结局指标
主要结局
Number of patients with adverse events (AEs) as a measure of safety and tolerability
时间窗: up to 4 weeks after last dose
AEs assessment via monitoring changes in clinical laboratory parameters (e.g. levels of liver, kidney, and bone marrow function) and ECG (e.g. QTc Interval).
次要结局
- Disease Control Rate (DCR)(up to approximately 24 months)
- Duration of Response (DOR)(up to approximately 24 months)
- Progression-free Survival (PFS)(up to approximately 24 months)
- Overall response rate (ORR)(up to approximately 24 months)
- Overall Survival (OS)(up to approximately 24 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of Tor Kinase Inhibitor in Advanced TumorsSolid TumorsNCT00731263AstraZeneca64
已完成
1 期
To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 DiabetesType 2 DiabetesNCT01176097AstraZeneca24
终止
1 期
Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic CancerPancreatic CancerNCT04131192Sunshine Lake Pharma Co., Ltd.13
终止
1 期
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.Advanced Solid TumorsTriple Negative Breast CancerChordoma and Alveolar Soft Part SarcomaNCT02936102Novartis Pharmaceuticals154
已完成
1 期
Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy SubjectsPainNCT00684502AstraZeneca110